Sajid Khan, MD is an Associate Professor of Surgery at Yale University School of Medicine. He earned his medical degree from the State University of New York Health Science Center at Syracuse and is Board Certified in both Complex General Surgical Oncology and General Surgery. He completed general surgery training at Oregon Health and Science University in Portland, OR and Albert Einstein College of Medicine/Montefiore in the Bronx, NY. He also completed a research fellowship in surgical oncology at Memorial Sloan-Kettering Cancer Center in New York, NY and a clinical and research fellowship in surgical oncology at The University of Chicago Medical Center in Chicago, IL. Watch a video with Dr. Sajid Khan >>

Dr. Khan is dedicated to improving the lives of patients with cancer through his clinical practice and research endeavors. His clinical practice specializes in the surgical management of patients with benign and malignant tumors of the liver, pancreas, bile ducts, gallbladder, stomach, and colon. Additionally he treats individuals diagnosed with cutaneous malignancies and soft tissue sarcomas, and cystic diseases of the pancreas. His commitment to the care of his patients incorporates a multidisciplinary team approach in addition to state of the art minimally invasive surgical techniques. He is an active member of the National Comprehensive Cancer Center (NCCN), Society of Surgical Oncology (SSO), Society of Surgery of the Alimentary Tract (SSAT), Southwest Oncology Group (SWOG), American College of Surgeons (ACS), American Society of Clinical Oncology (ASCO), Yale Center for Clinical Investigation (YCCI), Yale Cancer Center, and Yale School of Medicine Admissions Committee.

In addition to his clinical practice, Dr. Khan is also involved in clinical translational research studying cancer metastases and differences in tumor biology based on ethnicity/race and sex. Dr. Khan is an NIH-funded, well published, surgeon-scientist who seeks to use modern molecular biology to improve our understanding and treatment of patients with gastrointestinal cancers. Using molecular and clinical markers, he identifies patients with a limited number of metastases (oligometastasis) who will benefit from curative surgical resections. In addition, his lab studies the relationship with metabolite and protein expression on colon cancer patient outcomes based on race/ethnicity and sex. He also performs clinical outcomes research in all types of gastrointestinal cancers. Dr. Khan has been recognized for excellence in both clinical care and research in oncology.